Value of animal models for Chlamydia pneumoniae-related atherosclerosis

The evidence for a role of bacteria and viruses in cardiovascular disease

Inflammation plays a critical role in atherosclerosis and cardiovascular disease. Bacteria and viruses are major causative agents of inflammation in the body which normally develops as a response to infection. It is a logical extention, therefore, to believe bacterial and viral infections may be involved in a variety of presentations of cardiovascular diseases. The purpose of this review is to describe the data and conclusions to date on the involvement of these infectious agents in the induction of cardiovascular disease. The review also discusses the various specific bacteria and viruses that have been implicated in cardiovascular disease and the mechanisms, if known, that these agents induce cardiovascular disease.

Possibilities for therapeutic interventions in disrupting Chlamydophila pneumoniae involvement in atherosclerosis

Strong sero-epidemiologic, pathologic, and experimental evidence suggests that Chlamydophila pneumoniae (Cpn) infection may play a causative role in the development of atherosclerosis. Cpn is an obligate intracellular gram-negative bacterium that is responsible for 10% of cases of community-acquired pneumonia. In addition to its presence in the respiratory tract, live Cpn has been found within atherosclerotic plaques. Experimental findings have established Cpn's ability to infect vascular cells and elicit important atherogenic responses. Furthermore, Cpn infection can promote atherosclerotic development in different animal models. To date however, large-scale antibiotic clinical trials have not been effective in preventing major cardiovascular events. It is becoming apparent that Cpn undergoes a persistent state of infection, which is refractory to current chlamydial antibiotics. New treatment strategies that are effective toward acute and persistent forms of Cpn infection are needed in order to effectively eradicate the bacterium within the vascular wall. Possible therapeutics targets include Cpn-specific proteins and machinery directly involved in their survival, replication and maintenance. Alternatively, selectively targeting host cell pathways and machinery required for Cpn's actions in vascular cells also represent potential treatment strategies for atherosclerosis.

Update of antibiotic trials for secondary prevention of coronary heart disease

The possibility that infection is a stimulus for the vascular inflammation that promotes atherogenesis has spawned clinical trials of antibiotics. These have focused primarily on Chlamydia pneumoniae as a potential atherogenic agent. In contrast to pilot studies, recent large trials, capped by the Azithromycin and Coronary Events Study and PRavastatin Or AtorVastatin Evaluation and Infection Therapy mega trials, indicate that standard antibiotics (e.g., azithromycin and gatifloxacin) are ineffective for secondary cardiovascular prevention. Despite this, observations continue to mount that infection can be a stimulus for atherothrombosis. Thus, one should rethink, revise and reformulate hypotheses, and research strategies, including novel antibiotics and treatment at earlier stages of disease, rather than discard infection prematurely as a potential etiologic factor.

Chlamydia pneumoniae IgG serological status and venous thromboembolism: a cross-sectional hospital based study

OBJECTIVE

To search for a link between Chlamydia pneumoniae serological status and venous thromboembolic disease.

METHODS

From March 1992 to October 1999, we conducted a cross-sectional hospital-based study of consecutive unselected outpatients referred to us for clinical suspicion of venous thromboembolism. We compared the Chlamydia pneumoniae serological status with respectively, the venous thromboembolism, the deep vein thrombosis and the proximal deep vein thrombosis status.

RESULTS

Among 1193 patients registered for suspected venous thromboembolism, 1010 samples were available (499 negative and 511 positive patients for venous thromboembolism). Seventy-nine patients were Chlamydia pneumoniae positive. Our work failed to demonstrate any clear association between Chlamydia pneumoniae and venous thromboembolism status. Nevertheless, we identified a statistical difference regarding Chlamydia pneumoniae seropositivity and proximal vein thrombosis status (adjusted odds ratio of 1.70, CI95%: 1.05 to 2.77).

CONCLUSION

The presence of Chlamydia pneumoniae antibodies might be a minor risk factor for venous thrombosis.

Treatment with clarithromycin prior to coronary artery bypass graft surgery does not prevent subsequent cardiac events

BACKGROUND

Recently, it has been suggested that Chlamydia pneumoniae possibly plays a possible role in the pathogenesis of atherosclerosis. We investigated whether treatment with clarithromycin prior to coronary artery bypass graft (CABG) surgery would prevent subsequent cardiovascular events and mortality.

METHODS

Patients who were scheduled for CABG surgery were randomly assigned to receive either clarithromycin or placebo until the day of surgery in a double-blind trial. During the 2 years of follow-up, mortality and cardiovascular events were assessed.

RESULTS

Follow-up at 2 years was achieved for 473 patients. The mean duration of treatment was 16 days. Patient characteristics at baseline were well balanced between the 2 treatment groups. Mortality was equal in the 2 groups: 10 (4.2%) of 238 patients in the clarithromycin group and 9 (3.8%) of 235 patients in the placebo group (relative risk, 1.10; 95% CI, 0.42-2.89; P=1.0). Also, there were no significant differences in the proportion of patients who experienced cardiovascular events during the follow-up period: 20 (8.4%) of 238 patients in the clarithromycin group and 19 (8.1%) of 235 patients in the placebo group (relative risk, 1.04; 95% CI, 0.55-1.98; P=1.0). The overall rate of such events was 58 (12.3%) of 473 patients.

CONCLUSIONS

Treatment with clarithromycin in patients scheduled for CABG surgery did not reduce the subsequent occurrence of cardiovascular events or mortality during a 2-year follow-up period.

Infections, heat shock proteins, and atherosclerosis

Recent evidence indicates that infections or a pathogen burden contribute to the development and progression of atherosclerosis. While the mechanism of infection contributing to the pathogenesis is not fully elucidated, I hypothesize that heat shock proteins may be a link between infections and atherosclerosis. Heat shock proteins are a highly conserved family of proteins expressed in most cell types and have been shown to play a general role in protecting cells in response to stress. It has been demonstrated that Chlamydia and human HSP60 coexist in atherosclerotic lesions. Bacterial and human heat shock proteins have been found in soluble form in the general circulation of patients with atherosclerosis. Both heat shock proteins can stimulate cells to express adhesion molecules and proinflammatory cytokines. Certain organisms synthesize heat shock proteins that have close structural homology with human heat shock proteins. Because of the immunologic molecular mimicry between bacterial and human HSP60, it could be an autoantigen involved in eliciting cell-mediated and humoral immune responses that cause vessel injury leading to atherosclerosis. The aim of this review is to provide an update overview on the involvement of heat shock proteins in the pathogenesis of atherosclerosis in response to infections.

Changing the practice of cardiovascular medicine

Five large randomized trials of statins in primary and secondary prevention show the benefits of lipid-modifying therapy on cardiac morbidity and mortality. Evidence is beginning to accumulate showing that early and aggressive treatment of patients with acute coronary syndromes (acute myocardial infarction or unstable angina) can result in reduced mortality and morbidity and imparts a variety of mechanistic benefits. Nevertheless, recent surveys of coronary heart disease prevention in Europe and the US indicate that current evidence-based management of risk factors such as hypercholesterolemia is not uniformly employed. In fact, in Europe, only about a third of patients discharged from the hospital after an acute coronary syndrome are receiving prescriptions for statins. In US, more than a fourth of adults are eligible for treatment according to national guidelines but two thirds of them do not receive it. Among those treated, a considerable number do not reach their target levels. Therefore, strategies are needed to improve prescribing patterns among physicians and compliance among patients. It is essential that clinicians be aware of the evidence base supporting early and aggressive treatment of patients with acute coronary syndromes and that this is communicated to all clinicians involved in their care of patients with acute coronary syndromes.

Background and current knowledge of Chlamydia pneumoniae and atherosclerosis

Attributes of Chlamydia pneumoniae of potential importance to a relationship with atherosclerosis are described. Among these are that C. pneumoniae is not new. It is unique. It is a pathogen with which everyone is infected, and it is difficult to treat. It causes immunopathology, myocarditis, and endocarditis and chronicity is a hallmark of Chlamydia infection. Current knowledge of the relation of C. pneumoniae and atherosclerosis comes from observational (e.g., seroepidemiology and tissue studies) and experimental studies. The limitations of the serologic studies of chronic infection are noted as is the conclusive demonstration of an association of C. pneumoniae and atherosclerosis by the repeated and frequent finding of the organism in atherosclerotic tissue. Experimental studies are needed to determine if the association is causal. Such studies should include animal models, basic mechanisms, and secondary prevention antibiotic treatment trials.